Moderna shares climbed more than 20% in the first three trading days of 2026, marking the largest short-term advance since early 2022. For the first time since late 2021, the 50-day moving average crossed above the 200-day, forming a classic golden cross. Technical analysts view this pattern as a reliable indicator of sustained trend reversal rather than a fleeting bounce, given that the crossover occurred before price levels became overstretched.

Relative Strength Index (RSI) readings approached 70 without breaching overbought territory, signaling robust buying interest that has yet to peak. The MACD line has moved decisively into positive territory, reflecting accelerating upside momentum. Short-term simple moving averages (eight- and 20-day) remain stacked above longer-term averages, reinforcing conviction among trend-following traders that the current rally has room to run.

Investors reallocating from richly valued sectors have targeted discounted names, and Moderna’s emergence at this juncture underscores selective rotation into biotech. Despite the recent surge, the stock remains significantly below its 52-week high and closer to its annual low, a setup that tends to appeal to technical funds seeking early signals of a breakout. Market participants are adding the company to thematic watchlists focused on recovery plays in early 2026.

Moderna has submitted mRNA-1010 flu vaccine applications to major regulators in North America, Europe and Asia, aiming for launch targeting older adult populations next year. If approved, the shot could address an estimated market exceeding $3 billion annually by offering a multivalent seasonal platform. The filings complement a series of upward revisions in consensus earnings estimates, suggesting analysts are factoring in potential revenue streams beyond COVID-19 products.